Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study
Authors:
Open Access
Abstract
No abstract availableKeywords
Funding Information
- Bayer
- Amgen
- Merck
- Bristol-Myers Squibb
- Roche
- Sanofi
- Celgene
- Eli Lilly and Company
- Servier
This publication has 30 references indexed in Scilit:
- Maintenance Therapy With Cetuximab Every Second Week in the First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-7.5 Study by the Nordic Colorectal Cancer Biomodulation GroupClinical Colorectal Cancer, 2015
- Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer GroupThe Lancet, 2015
- International Society of Geriatric Oncology Consensus on Geriatric Assessment in Older Patients With CancerJournal of Clinical Oncology, 2014
- Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trialThe Lancet Oncology, 2014
- Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicitiesSupportive Care in Cancer, 2011
- Sex Differences in Pharmacokinetics and PharmacodynamicsClinical Pharmacokinetics, 2009
- Clinical Predictors of Severe Cetuximab-Induced Rash: Observations from 933 Patients Enrolled in North Central Cancer Treatment Group Study N0147Oncology, 2008
- Crosstalk between EGFR and Extranuclear Steroid ReceptorsAnnals of the New York Academy of Sciences, 2006
- Differences in toxicity between men and women treated with 5‐fluorouracil therapy for colorectal carcinomaCancer, 2005
- Influence of Sex on Toxicity and Treatment Outcome in Small-Cell Lung CancerJournal of Clinical Oncology, 2005